Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital

BACKGROUND: Sacubitril/valsartan has been incorporated into guidelines based on the results of the PARADIGM-HF trial, which demonstrated reduced mortality in stable patients with heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan is recommended in addition to other HF therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peppin, Katie L., Tellor, Katie B., Armbruster, Anastasia L., Schwarze, Martin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034425/
https://www.ncbi.nlm.nih.gov/pubmed/32128057
http://dx.doi.org/10.1080/20009666.2019.1708638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034425/
https://www.ncbi.nlm.nih.gov/pubmed/32128057
http://dx.doi.org/10.1080/20009666.2019.1708638

Ejemplares similares